Comment on basal insulin plus bolus insulin or better plus GLP1-RA?

被引：0

作者：

Ritzel, Robert A. ^{[1
,2
]}

机构：

[1] Klin Bogenhausen, Chefarzt Endokrinol Diabetol & Angiol, Munich, Germany

[2] Klin Schwabing, Munich, Germany

来源：

DIABETOLOGIE UND STOFFWECHSEL | 2024年 / 19卷 / 01期

关键词：

D O I：

10.1055/a-2167-7456

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：30 / 31

页数：2

共 50 条

[41] Comparison of the cost-effectiveness for basal-bolus therapy of type-1 diabetes using insulin detemir plus insulin aspart or human insulin-based regimens in the Netherlands
Valentine, WJ
Wittrup-Jensen, K
Palmer, AJ
Roze, S
VALUE IN HEALTH, 2005, 8 (03) : 255 - 255
[42] Efficacy and Safety of IDegLira (Combination of Insulin Degludec plus Liraglutide), in Insulin-Naive Patients with T2D Uncontrolled on GLP-1 Receptor Agonist (GLP-1RA) Therapy
Linjawi, Sultan
Bode, Bruce W.
Chaykin, Louis B.
Courreges, Jean-Pierre
Handelsman, Yehuda
Lehmann, Lucine
Mishra, Abhishek
Simpson, Richard W.
DIABETES, 2015, 64 : A255 - A255
[43] Expanding the Basal-Plus Regimen: Basal Insulin plus Lixisenatide Is More Likely to Achieve the Composite Outcome Of Hba1c <7%, No Documented Symptomatic Hypoglycemia and No Weight Gain Compared With Basal plus Prandial Insulin
Rosenstock, Julio
Germe, Maeva
Wang, Edward
Lin, Jay
Bonadonna, Riccardo C.
De Pablos-Velasco, Pedro
Roussel, Ronan
Raccah, Denis
DIABETES, 2013, 62 : A262 - A262
[44] Evidence for Basal–Bolus Insulin Versus Slide Scale Insulin
Sameer Badlani
William T. Ford
David J. Yu
Gerard X. Brogan
Charles V. Pollack
Gregory A. Volturo
Current Emergency and Hospital Medicine Reports, 2014, 2 (1) : 26 - 34
[45] Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections
Riddle, M. C.
Rosenstock, J.
Vlajnic, A.
Gao, L.
DIABETES OBESITY & METABOLISM, 2014, 16 (05): : 396 - 402
[46] Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) plus Basal Insulin vs. GLP-1RA in Type 2 Diabetes Mellitus-A Systematic Review and Meta-analysis
Satti, Muniza M.
O'Brien, Timothy
Liew, Aaron
DIABETES, 2018, 67
[47] Intensive insulin therapy compared to weekly administration of a GLP-1 receptor agonist plus basal insulin Randomized study in people with inadequately controlled type 2 diabetes
Jecht, Michael
DIABETOLOGE, 2020, 16 (08): : 742 - 743
[48] An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK
Palmer, Andrew J.
Valentine, William J.
Ray, Joshua A.
Foos, Volker
Lurati, Francesco
Smith, Inger
Lammert, Morten
Roze, Stephane
CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (04) : 895 - 901
[49] A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes
Hirsch, Irl B.
Beck, Roy W.
Marak, Martin C.
Kudva, Yogish
Akturk, Halis K.
Bhargava, Anuj
Codorniz, Kevin
Diner, Jamie
Aleppo, Grazia
Blevins, Thomas
Levy, Carol J.
Raskin, Philip
Castorino, Kristin
Manessis, Anastasios
Pickering, David
Steenkamp, Devin W.
Weinstock, Ruth S.
Bode, Bruce W.
Hamdy, Osama
Nguyen, Quang T.
Kipnes, Mark
Ruedy, Katrina J.
Desjardins, Donna
Haider, Zehra
Jacobson, Christopher
Lee, Scott
Buse, John B.
Klein, Klara Rachel
O'Malley, Grenye
Church, Mei Mei
Mottalib, Adham
Baran, Jesica D.
Kurek, Corey
Rizvi, Shafaq
Donahue, Cassandra
Tamarez, Denisa
Castillo, Astrid Atakov
Borgman, Sarah
Frey, Sarah
Calhoun, Peter
DIABETES CARE, 2025, 48 (03) : 353 - 360
[50] Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study
Abdul-Ghani, Muhammad
Migahid, Osama
Megahed, Ayman
Adams, John
Triplitt, Curtis
DeFronzo, Ralph A.
Zirie, Mahmoud
Jayyousi, Amin
DIABETES CARE, 2017, 40 (03) : 325 - 331

← 1 2 3 4 5 →